Pfizer on Tuesday said patient safety and product quality are its highest priorities, reacting to the Karnataka Food and Drug Administration’s (FDA) action regarding the circulation of counterfeit drugs.
Pfizer stated that it continues to work closely with authorities to resolve the open queries, emphasising that its focus remains on protecting patients, safeguarding public health and maintaining confidence in the healthcare system. The Karnataka health regulator on Sunday said it has cancelled 16 drug licences of retailers and wholesalers and suspended eight others in connection with the alleged distribution and sale of spurious medicines. The Karnataka FDA’s action followed an inspection by its drug-enforcement wing on August 18, when an alleged unlicensed pharmaceutical repacking-and-relabelling operation was busted at a farmhouse in Kurubarakeranahalli, Bidadi, in Bengaluru South district.
“Patient safety and product quality are of the highest priority for us at Pfizer,” the company said in a statement late on Tuesday evening.
